Biological Therapy on Cardiovascular Risk Factors in RA: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Diana Popescu
,
Elena Rezus
,
Minerva Codruta Badescu
,
Nicoleta Dima
,
Petronela Nicoleta Seritean Isac
,
Ioan-Teodor Dragoi
,
Ciprian Rezus

Rheumatoid arthritis (RA), one of the most common of the chronic inflammatory autoimmune diseases (CIADs), is recognized as an independent cardiovascular risk factor. Therapies used in RA include disease-modifying antirheumatic drugs (DMARDs), categorized into conventional synthetic DMARDs (csDMARDs), targeted synthetic DMARDS (tsDMARDs), and biological DMARDs (bDMARDs). csDMARDs are used as first-line therapy in the absence of contraindications, with Methotrexate (MTX) being the first option. Moreover, when disease activity is high, low doses of glucocorticoids can be used for a short period of time as a bridging therapy.

  • atherosclerosis
  • autoimmune disease
  • rheumatoid arthritis
  • inflammation

1. Anti-IL-6

Interleukin-6 (IL-6) is a cytokine with pleiotropic effects in inflammation, modulation of immune responses, regenerative processes, hematopoiesis, and metabolism. Synthesized from the initial stage at the site of inflammation by several cell types—such as macrophages, adipocytes, endothelial cells (ECs), or smooth muscle cells—IL-6 causes the release of acute-phase reactants from the liver, such as C-reactive protein (CRP), fibrinogen, haptoglobin, and serum amyloid A (SAA). It is important to note that the transition from the acute to the chronic phase of inflammation is made by the recruitment of the leukocyte infiltrates, while neutrophils are transformed into monocytes or macrophages. In this stage, an important role is played by the soluble IL-6 receptor α (sIL-6Rα) [1][2]. Its important role in the acute and chronic phases of inflammation has made this particular cytokine a key player in the development and progression of atherosclerosis. There are studies that have demonstrated the role of IL-6 as a risk factor for coronary atherosclerosis. For example, Saremi et al. [3] showed an association between IL-6 values and coronary artery calcium (CAC), independent of other cardiovascular risk factors. Another study [4] highlighted a link between increased IL-6 levels and myocardial infarction (MI) risk. Studies in this direction have laid the groundwork for the hypothesis that IL-6 could be a therapeutic target for atherosclerosis.
The first anti-IL-6 drug approved for the treatment of RA, tocilizumab (TCZ), has been investigated in several studies. Clear data showing changes in lipid profiles—specifically in the serum lipid levels—have raised concerns about increased cardiovascular risk secondary to the dyslipidemic process. The MEASURE study [5] showed that adding TCZ to MTX increased total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), and triglycerides more than MTX alone; in addition, another report compared monotherapy with TCZ with monotherapy with MTX, with the results favoring MTX in terms of lipid profile [6]. In another study, TCZ alone resulted in greater increases in TC and LDL-C than the combination of two csDMARDs (MTX plus hydroxychloroquine) [7]; meanwhile, in the ADACTA study, comparing TCZ with another bDMARD, TCZ had a more pronounced impact on serum lipid levels than adalimumab [8]. Further analysis concluded that although these changes in lipid profile occurred, long-term use of TCZ reduced the cardiovascular risk due to atherosclerosis. The explanation was found in the same studies, which showed that although TCZ had a negative impact on serum lipid levels, its effects on lipid function and quality were beneficial. Therefore, it was observed that the increase in serum lipids led to an improvement in inflammation, with a reduction in inflammatory markers such as fibrinogen, D-dimer, phospholipase A2, and SAA [5][7][8]. This makes the lipid changes more anti-atherogenic than pro-atherogenic [9]. Furthermore, using TCZ was linked to lower lipoprotein(a) (Lp(a)) concentrations [5][8][10]. Future studies should aim to translate these pro-atherosclerotic risk reduction effects of TCZ to patients without RA. The ASSAIL-IM study, still in phase II, has already demonstrated some data and aims to assess whether TCZ can reduce myocardial damage in patients with atherosclerotic cardiovascular disease (ASCVD) [11][12].
Aside from quantitative and qualitative changes, TCZ improves endothelial function and decreases oxidative stress, expression of vascular cell adhesion moll=ecule (VCAM), and pro-thrombotic status by modulating the pro-thrombotic and pro-inflammatory phenotype of monocytes; it also induces NETosis [13].
The impact of TCZ on arterial stiffness—an independent predictor of cardiovascular risk—has also been evaluated. The results were either conflicting [7] or showed that TCZ reduces pulse wave velocity (PWV) [14][15], while carotid intima-media thickness (cIMT) was not influenced [15]. Regarding traditional cardiovascular risk factors, there were no significant changes in blood pressure (BP) [15], but there was a higher prevalence of arterial hypertension among patients treated with TCZ than among those treated with MTX [16]. TCZ also improved the distribution of fat to peripheral tissues and the skeletal muscle mass index [17].
Compared to other bDMARDs, TCZ has a reduced risk of major acute cardiovascular event (MACE), being superior to abatacept [18] and anti-TNF-α [19], but with no major differences between it and adalimumab or etanercept [19].
Sarilumab, the other monoclonal antibody that binds to the IL-6 receptor, seems to have similar efficacy to TCZ in terms of clinical and radiological improvement of RA [20], while being clinically and functionally superior to adalimumab [21]. The incidence of MACE with sarilumab, whether in combination with csDMARDs or as monotherapy, did not differ from that in patients without DMARDs [22]. Although the changes in lipid profile are the same, studies on the relationship between sarilumab and cardiovascular risk are limited compared to those on TCZ.

2. Anti-TNF-α

Tumor necrosis factor-α (TNF-α), a cytokine produced by activated macrophages and monocytes as well as natural killer (NK) cells, plays a key role in the pathogenesis of RA, due to its pro-inflammatory effects. It is also involved in defending organisms against infection, bone remodeling, and cancer. Increased endothelial permeability to circulating blood cells, nitric oxide (NO) reduction, reactive oxygen species (ROS) production, and the ability to promote dyslipidemia and insulin resistance are mechanisms underlying atheromatous plaque formation [23][24]. It is worth noting that patients with MI who were being monitored for recurrence of MACE showed steadily increased TNF-α levels [25]. Understanding the mechanisms of action of this cytokine has led to the development of targeted therapies such as TNF-α inhibitors. 
Data from studies and clinical trials show a reduction in cardiovascular risk in patients treated with TNF-α inhibitors. Comparative studies between anti-TNF-α drugs and csDMARDs demonstrated a 20–30% reduction in cardiovascular risk in the first six months after the introduction of anti-TNF-α drugs [26]. Moreover, anti-TNF-α drugs may reduce the risk of all acute cardiovascular events, but especially of MI or stroke, as suggested by two meta-analyses. [27]. The cardioprotective effect increases proportionally the faster the bDMARDs with anti-TNF-α activity are introduced, but also the longer they are maintained [28]. This is also supported by two other studies in which an increased cardiovascular risk was observed upon [29] and within 6 months of [30] bDMARDs’ discontinuation. In addition to the impact on the occurrence of an acute cardiovascular event such as MI, anti-TNF-α therapy may influence the prognosis of patients after such an event. As regards post-MI mortality, Low et al. [28] demonstrated that patients in whom bDMARDs were stopped 3 months prior to the MI had a threefold higher mortality rate than those receiving anti-TNF-α drugs. No correlation was found between severity or mortality rate and TNF-α inhibitors versus csDMARDs in this study [28]. However, these effects do not apply to all patients, since Ljung et al. [31] showed that patients with low disease activity (as assessed by DAS-28)—referred to as responders—had a 50% lower rate of developing acute coronary syndrome compared to non-responders.
Insights on the effects of anti-TNF-α drugs on the lipid profile have conflicting results. Some studies have reported a significant increase in TC, LDL-C, HDL-C, or ApoA1 and ApoB [32][33], while others have shown no effect on TC and its fractions or triglycerides [34][35] for adalimumab. There was no effect of adalimumab on cholesterol efflux despite inhibiting cholesterol uptake in macrophages [35]. Infliximab, on the other hand, seems to have greater effects on serum lipid levels, with most of the studies proving that it can induce long-lasting increases in TC, LDL-C, HDL-C, and triglycerides [36][37]. In patients treated with golimumab and MTX, increases in TC, LDL-C, and HDL-C were observed compared to those receiving monotherapy with MTX [38], while for certolizumab there are non-specific data available [31][32]. As for etanercept, the ApoB/ApoA ratio was significantly lower in responders among RA patients, while HDL-C increased significantly, with these results demonstrating its favorable effects on the lipid profile [39]. No significant change in LDL-C or triglycerides was reported [39][40].
There is evidence that TNF-α inhibitors have a positive effect on endothelial dysfunction, although this has been observed mainly in patients without many cardiovascular risk factors [41]. Improvements have also been seen in NO bioavailability and ROS production in patients treated with both infliximab and MTX [42]. Low levels of SAA [33] and ADMA [43], along with reduced levels of inflammatory markers such as CRP, phospholipase A2, or fibrinogen, further help to improve cardiovascular risk.
Effects of anti-TNF-α therapy on arterial stiffness showed significant reduction for adalimumab, etanercept, and infliximab after 8–56 weeks of follow-up, independent of other factors such as clinical response or age. The impact appeared to be more pronounced for the first two than for infliximab [44][45][46]. There were no effects reported on cIMT [14][33][45], except for one study showing that anti-TNF-α therapy may be effective in slowing the progression of cIMT, but this is dependent on the long-term disease [47]. As for the impact on traditional cardiovascular risk factors, insulin resistance appeared to improve with infliximab therapy [36]. Although there is evidence that patients receiving TNF-α inhibitors present a risk of developing arterial hypertension [48], many studies do not show a direct correlation between them [34][37]. Nevertheless, monitoring BP during bDMARDs should be part of the therapeutic management.
Regarding the risk of developing acute cardiovascular events, there is evidence showing that the risk for the occurrence of MACE is lower in patients treated with etanercept compared to TCZ [49] or tofacitinib (a janus kinase inhibitor) [50], while another study found no difference in the risk of MACE between patients treated with tofacitinib and with adalimumab [51].

3. Anti-CD20

In addition to previously described mechanisms involved in the pathogenesis of atherosclerosis, B-cell activation plays an important role by stimulating T-helper1 (Th1), with a pro-atherogenic effect, and inhibiting IL-17, with an anti-atherogenic effect [52]. Both B1 (by producing IgM antibodies) and B2 have been shown to promote atherosclerosis [53]. Moreover, B cells stimulate the production of different cytokines, such as IL-6, IL-8, IL-10, and TNF-α [54]. Finally, anti-CD20 treatment, through the consumption of B2 cells, slows the progression of atherosclerosis [55]. There is some evidence demonstrating the potential anti-atherogenic role of anti-CD20 treatment. Treatment with anti-CD20 drugs in mice led to decreased infarct area and improved cardiac remodeling [56].
Rituximab (RTX), a monoclonal CD20 antibody, works by depleting B2 cells. It has been shown to be effective in the treatment of RA, by improving clinical symptoms and slowing disease progression. RTX is a second-line biologic agent, used in case of therapeutic failure of another bDMARD [57].
Significant increases in HDL-C along with decreases in the ApoB/ApoA1 ratio (seen as an atherogenic index) have been reported, while TC and triglycerides were increased in two studies [58][59]. However, other studies showed no changes in HDL-C or triglycerides, along with significant increases in TC and LDL-C [15][58]. Due to conflicting findings, further studies are needed to elucidate the impact of RTX on lipid profiles.
There was no significant effect on BP, or on PWV, as demonstrated in three studies [15][60][61], although in one study an improvement in cIMT was observed [61].
Improved cardiovascular risk in patients treated with RTX may also result from reduced inflammatory status, with studies showing decreases in CRP, VSH, DAS-28 [59], and SAA [58], as well as enhanced endothelial function [62].
According to the literature, the reduction in the risk of acute cardiovascular events such as MIs using RTX is similar to that from using anti-TNF-α drugs [63].

4. Anti-CD80/86

T cells play a pivotal role in the immune response in native atherosclerosis. Abatacept shows strong clinical promise for cardiovascular risk prevention, since T-cell CD28-CD80/86 co-stimulation is essential for accelerated atherosclerosis [64].
Assessing factors that influence cardiovascular risk, studies have not reported changes in TC, triglycerides, LDL-C, or HDL-C levels for abatacept [15][65]. There is one study showing an increase in LDL-C [66], while there two showing improvements in HDL-C, both quantitatively and qualitatively [66][67]. No significant modification in cIMT [15][68] or BP [15] was observed, while BMI showed an upward trend; however, insulin sensitivity appeared to be improved [69].
Compared to other bDMARDs—specifically, to TNF-α inhibitors—abatacept demonstrated better cardioprotective effects [18][70]. Jin et al., in their review [68], noted that patients treated with abatacept had a 28% lower risk of MACE compared with anti-TNF-α therapy and a 36% increased risk of MACE compared with those starting TCZ; nevertheless, only the composite outcome showed this effect of TCZ. In another study, this characteristic was only found in patients with diabetes mellitus [71].

This entry is adapted from the peer-reviewed paper 10.3390/life13020319

References

  1. Schett, G. Physiological effects of modulating the interleukin-6 axis. Rheumatology 2018, 57, 43–50.
  2. Tanaka, T.; Narazaki, M.; Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 2014, 6, a016295.
  3. Saremi, A.; Anderson, R.J.; Luo, P.; Moritz, T.E.; Schwenke, D.C.; Allison, M.; Reaven, P.D. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis 2009, 203, 610–614.
  4. Ridker, P.M.; Rifai, N.; Stampfer, M.J.; Hennekens, C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101, 1767–1772.
  5. McInnes, I.B.; Thompson, L.; Giles, J.T.; Bathon, J.M.; Salmon, J.E.; Beaulieu, A.D.; Codding, C.E.; Carlson, T.H.; Delles, C.; Lee, J.S.; et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann. Rheum. Dis. 2015, 74, 694–702.
  6. Cacciapaglia, F.; Anelli, M.G.; Rinaldi, A.; Fornaro, M.; Lopalco, G.; Scioscia, C.; Lapadula, G.; Iannone, F. Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment. Mediat. Inflamm. 2018, 2018, 2453265.
  7. Kawashiri, S.Y.; Kawakami, A.; Yamasaki, S.; Imazato, T.; Iwamoto, N.; Fujikawa, K.; Aramaki, T.; Tamai, M.; Nalamura, H.; Ida, H.; et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol. Int. 2011, 31, 451–456.
  8. Gabay, C.; McInnes, I.B.; Kavanaugh, A.; Tuckwell, K.; Klearman, M.; Pulley, J.; Sattar, N. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Clin. Trial 2016, 75, 1806–1812.
  9. Greco, D.; Gualtierotti, R.; Agosti, P.; Adorni, M.P.; Ingegnoli, F.; Rota, M.; Bernini, F.; Meroni, P.L.; Ronda, N. Anti-atherogenic modification of serum lipoprotein function in patients with rheumatoid arthritis after tocilizumab treatment, a pilot study. J. Clin. Med. 2020, 9, 2157.
  10. Garcia-Gomez, C.; Martin-Martinez, M.A.; Castaneda, S.; Sanchez-Alonso, F.; Uriarte-Ecenarro, M.; Gonzalez-Juanatey, C.; Romera-Baures, M.; Santos-Rey, J.; Pinto-Tasende, J.A.; Quesada-Masachs, E. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the cardiovascular in rheumatology study project. J. Clin. Lipidol. 2017, 11, 749–756.
  11. Broch, K.; Anstensrud, A.K.; Woxholt, S.; Sharma, K.; Tollefsen, I.M.; Bendz, B.; Aakhus, S.; Ueland, T.; Amundsen, B.H.; Damas, J.K.; et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 2021, 77, 1845–1855.
  12. Huse, C.; Anstensrud, A.K.; Michelsen, A.E.; Ueland, T.; Broch, K.; Woxholt, S.; Yang, K.; Sharma, K.; Tollefsen, I.M.; Bendz, B.; et al. Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial. Lancet 2022, 80, 104013.
  13. Ruiz-Limon, P.; Ortega, R.; de la Rosa, I.A.; Abalos-Aguilera, M.C.; Perez-Sanchez, C.; Jimenez-Gomez, Y.; Peralbo-Santaella, E.; Font, P.; Ruiz-Vilches, D.; Ferrin, G. Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Transl. Res. 2017, 183, 87–103.
  14. Kume, K.; Amano, K.; Yamada, S.; Hatta, K.; Ohta, H.; Kuwaba, N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: An open-label randomized controlled trial. J. Rheumatol. 2011, 38, 2169–2171.
  15. Provan, S.A.; Berg, I.J.; Berner Hammer, H.; Mathiessen, A.; Kvien, T.K.; Semb, A.G. The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: A 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, abatacept and tocilizumab. PLoS ONE 2015, 10, e0130709.
  16. Jones, G.; Sebba, A.; Lowenstein, M.B.; Calvo, A.; Gomez-Reino, J.J.; Siri, D.A.; Tomsic, M.; Alecock, E.; Woodworth, T.; Genovese, M.C. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann. Rheum. Dis. 2010, 69, 88–96.
  17. Tournadre, A.; Pereira, B.; Dutheil, F.; Giraud, C.; Courteix, D.; Sapin, V.; Frayssac, T.; Mathieu, S.; Malochet-Guinamand, S.; Soubrier, M. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J. Cachexia Sarcopenia Muscle 2017, 8, 639–646.
  18. Zhang, J.; Xie, F.; Yun, H.; Chen, L.; Muntner, P.; Levitan, E.B.; Safford, M.M.; Kent, S.T.; Osterman, M.T.; Lewis, J.D.; et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann. Rheum. Dis. 2016, 75, 1813–1818.
  19. Singht, S.; Fumery, M.; Singh, A.G.; Singh, N.; Prokop, L.J.; Dulai, P.S.; Sandborn, W.J.; Curtis, J.R. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Care Res. 2020, 72, 561–576.
  20. Emery, P.; Rondon, J.; Parrino, J.; Lin, Y.; Pena-Rossi, C.; van Hoogstraten, H.; Graham, N.M.H.; Liu, N.; Paccaly, A.; Wu, R.; et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology 2019, 58, 849–858.
  21. Burmester, G.R.; Lin, Y.; Patel, R.; van Adelsberg, J.; Mangan, E.K.; Graham, N.M.H.; van Hoogstraten, H.; Bauer, D.; Vargas, J.I.; Lee, E.B. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): A randomised, double-blind, parallel-group phase III trial. Ann. Rheum. Dis. 2017, 76, 840–847.
  22. Fleischmann, R.; Genovese, M.C.; Lin, Y.; St John, G.; van der Heijde, D.; Wang, S.; Gomez-Reino, J.J.; Maldonado-Cocco, J.A.; Stanislav, M.; Kivitz, A.J.; et al. Long-term safety of sarilumab in rheumatoid arthritis: An integrated analysis with up to 7 years’ follow-up. Rheumatology 2020, 59, 292–302.
  23. Smole, J.S.; Aletaha, D.; Barton, A.; Burmester, G.R.; Emery, P.; Firestein, G.S.; Kavanaugh, A.; McInnes, I.B.; Solomon, D.H.; Strand, V.; et al. Rheumatoid arthritis. Nat. Rev. Dis. Primers 2018, 4, 18001.
  24. Jang, D.; Lee, A.H.; Shin, H.Y.; Song, Y.R.; Park, J.H.; Kang, T.B.; Lee, S.R.; Yang, S.H. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int. J. Mol. Sci. 2021, 22, 2791.
  25. Ridker, P.M.; Rifai, N.; Pfeffer, M.; Sacks, F.; Braunwald, E. Elevation of tumor necrosis factor-alpha and increased risk of reccurrent coronary events after myocardial infarction. Circulation 2000, 101, 2149–2153.
  26. Solomon, D.H.; Curtis, J.R.; Saag, K.G.; Lii, J.; Chen, L.; Harrold, L.R.; Herrinton, L.J.; Graham, D.J.; Kowal, M.K.; Kuriya, B.; et al. Cardiovascular risk in rheumatoid arthritis: Comparing TNF-α blockade with nonbiologic DMARDs. Am. J. Med. 2013, 126, 9–17.
  27. Roubille, C.; Richer, V.; Starnino, T.; McCourt, C.; McFarlane, A.; Fleming, P.; Siu, S.; Kraft, J.; Lynde, C.; Pope, J.; et al. The effects of tumor necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Ann. Rheum. Dis. 2015, 74, 480–489.
  28. Low, A.S.L.; Symmons, D.P.M.; Lunt, M.; Mercer, L.K.; Gale, C.P.; Watson, K.D.; Dixon, W.G.; Hyrich, K.L. Relationship between exposure to tumor necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2017, 76, 654–660.
  29. Lee, J.L.; Sinnthurai, P.; Buchbinder, R.; Hill, C.; Lassere, M.; March, L. Biologics and cardiovascular events in inflammatory arthritis: A prospective national cohort study. Atrhritis Res. Ther. 2018, 20, 171.
  30. Karpouzas, G.A.; Orsmeth, S.R.; Hernandez, E.; Budoff, M.J. Biologics may prevent cardiovascular events in rheumatoid arthritis by inhibiting coronary plaque formation and stabilizing high-risk lesions. Arthritis Rheumatol. 2020, 72, 1467–1475.
  31. Ljung, L.; Rantapaa-Dahlqvist, S.; Jacobsson, L.T.H.; Askling, J. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann. Rheum. Dis. 2016, 75, 2087–2094.
  32. Bergstrom, U.; Jovinge, S.; Persson, J.; Jacobsson, L.T.H.; Turesson, C. Effects of treatment with adalimumab on blood lipid levels and atherosclerosis in patients with rheumatoid arthritis. Curr. Ther. Res. Clin. Exp. 2018, 89, 1–6.
  33. Gabay, C.; Emery, P.; van Vollenhoven, R.; Dikranian, A.; Alten, R.; Pavelka, K.; Klearman, M.; Musselman, D.; Agarwal, S.; Green, J.; et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. Lancet 2013, 381, 1541–1550.
  34. Gonzalez-Juanatey, C.; Vasquez-Rodriguez, T.R.; Miranda-Filloy, J.A.; Gomez-Acebo, I.; Testa, A.; Garcia-Porrua, C.; Sanchez-Andrade, A.; Llorca, J.; Gonzalez-Gay, M.A. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediat. Inflamm. 2012, 2012, 674265.
  35. Ronda, N.; Greco, D.; Adorni, M.P.; Zimetti, F.; Favari, E.; Hjeltnes, G.; Mikkelsen, L.; Borghi, M.O.; Favalli, E.G.; Gatti, R.; et al. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: Complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol. 2015, 67, 1155–1164.
  36. Biseell, L.A.; Hensor, E.M.A.; Kozera, L.; Mackie, S.L.; Burska, A.N.; Nam, J.L.; Keen, H.; Villeneuve, E.; Donica, H.; Buch, M.H. Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensinve treatment of early rheumatoid arthritis-results from the IDEA study. Rheumatology 2016, 55, 2181–2190.
  37. Popa, C.; van Tits, L.J.H.; Barreta, P.; Lemmers, H.L.M.; van den Hoogen, F.H.J.; van Riel, P.L.C.; Radstake, T.R.D.J.; Netea, M.G.; Roest, M.; Stalenhoef, A.F.H. Anti-inflammatory therapy with tumor necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann. Rheum. Dis. 2009, 68, 868–872.
  38. Kirkham, B.W.; Wasko, M.C.; Hsia, E.C.; Fleischmann, R.M.; Genovese, M.C.; Matteson, E.L.; Liu, H.; Rahman, M.U. Effects of golimumab, an anti-tumor necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann. Rheum. Dis. 2014, 73, 161–169.
  39. Daien, C.I.; Fesler, P.; du Cailar, G.; Daien, V.; Mura, T.; Dupuy, A.M.; Cristol, J.P.; Ribstein, J.; Combe, B.; Morel, J. Etanercept normalises left ventricular mass in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2013, 72, 881–887.
  40. Rodriguez-Jimenez, N.A.; Garcia-Gonzalez, C.E.; Ayala-Lopez, K.P.; Trujillo-Hernandez, B.; Aguilar-Chavez, E.A.; Rocha-Munoz, A.D.; Vasquez-Jimenez, J.C.; Olivas-Flores, E.; Salazar-Paramao, M.; Corona-Sanchez, E.G.; et al. Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: Results of an observational 24-weeks cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy. Biomed Res. Int. 2014, 2014, 510305.
  41. Ursini, F.; Leporini, C.; Bene, F.; D’Angelo, S.; Mauro, D.; Russo, E.; De Sarro, G.; Olivieri, I.; Pitzalis, C.; Lewis, M.; et al. Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: A systematic review and meta-analysis. Sci. Rep. 2017, 7, 5346.
  42. O’Neill, F.; Charakida, M.; Topham, E.; McLoughlin, E.; Patel, N.; Sutill, E.; Kay, C.W.M.; D’Aiuto, F.; Landmesser, U.; Taylor, P.C.; et al. Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis. Heart 2017, 103, 766–773.
  43. Spinelli, F.R.; Metere, A.; Barbati, C.; Pierdominici, M.; Iannuccelli, C.; Lucchino, B.; Ciciarello, F.; Agati, L.; Valesini, G.; Di Franco, M. Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis. Mediat. Inflamm. 2013, 2013, 537539.
  44. Kume, K.; Amano, K.; Yamada, S.; Hatta, K.; Amano, K.; Ohta, H.; Kuwaba, N. Tocilizumab improves arterial stiffness as well as other biologics with methtrexate-resistant active rheumatoid arthritis—An opel label, randomized cohort multi center study. J. Radiol. 2015, 4, 186.
  45. Tam, L.S.; Shang, Q.; Li, E.K.; Wang, S.; Li, R.J.; Lee, K.L.; Leung, Y.Y.; Ying, K.Y.; Ym, C.W.; Kun, E.W.; et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis—A randomized trial. J. Rheumatol. 2012, 39, 2267–2275.
  46. Angel, K.; Provan, S.A.; Fagerhol, M.K.; Mowinckel, P.; Kvien, T.; Atar, D. Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: A controlled study. Am. J. Hypertens. 2012, 25, 644–650.
  47. Tam, L.S.; Kitas, G.D.; Gonzalez-Gay, M.A. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology 2014, 53, 1108–1119.
  48. Zhao, Q.; Hong, D.; Zhang, Y.; Sang, Y.; Yang, Z.; Zhang, X. Association between anti-TNF therapy for rheumatoid arthritis and hypertension: A meta-analysis of randomized controlled trials. Medicine 2015, 94, 731.
  49. Giles, J.T.; Sattar, N.; Gabriel, S.; Ridker, P.M.; Gay, S.; Warne, C.; Musselman, D.; Brockwell, L.; Shittu, E.; Klearman, M.; et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: A randomised controlled trial. Arthritis Rheum. 2019, 72, 31–40.
  50. Charles-Schoeman, C.; Buch, D.H.; Dougados, M.; Bhatt, D.L.; Giles, J.T.; Ytterberg, S.R.; Koch, G.G.; Vranic, I.; Wu, J.; Wang, C.; et al. Risk of major adverse cardiovascular events with tofacitinib versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: A post hoc analysis from ORAL Surveillance. Ann. Rheum. Dis. 2022, 81, 119–129.
  51. Hoisnard, L.; Vegas, L.P.; Dray-Spira, R.; Weill, A.; Zureik, M.; Sbidian, E. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: A nationwide cohort study. Ann. Rheum. Dis. 2022, 74.
  52. Ait-Oufella, H.; Herbin, O.; Bouaziz, J.D.; Binder, C.J.; Uyttenhove, C.; Laurans, L.; Taleb, S.; Van Vre, E.; Esposito, B.; Vilar, J.; et al. B cell depletion reduces the development of atherosclerosis in mice. J. Exp. Med. 2010, 207, 1579–1587.
  53. Tsiantoulas, D.; Diehl, C.J.; Witztum, J.L.; Binder, C.J. B cells and humoral immunity in atherosclerosis. Circ. Res. 2014, 114, 1743–1756.
  54. Correa, J.E.B.; Cortez, M.A.F.; Uribe, J.A.; Camacho, L.S.R. Comparison of plasma cytokine levels before and after treatment with rituximab in patients with rheumatoid arthritis and systemic lupus erythematosus-associated polyautoimmunity. Univ. Med. 2018, 59, 21–36.
  55. Srikakulapu, P.; McNamara, C.A. B cells and atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2017, 312, 1060–1067.
  56. Tsiantoulas, D.; Sage, A.P.; Mallat, Z.; Binder, C.J. Targeting B cells in atherosclerosis: Closing the gap from bench to bedside. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 296–302.
  57. Smolen, J.S.; Landewe, R.B.M.; Bijlsma, J.W.; Burmester, G.R.; Dougados, M.; Kerschbaumer, A.; McInnes, I.B.; Sepriano, A.; van Vollenhoven, R.F.; de Wit, M.; et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 2020, 79, 685–699.
  58. Raterman, H.G.; Levels, H.; Voskuyl, A.E.; Lems, W.F.; Dijkmans, B.A.; Nurmohamed, M.T. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann. Rheum. Dis. 2013, 72, 560–565.
  59. Novikova, D.S.; Popkova, T.V.; Lukina, G.V.; Luchikhina, E.L.; Karateev, D.E.; Volkov, A.V.; Novikov, A.A.; Aleksandrova, E.N.; Nasonov, E.L. The effects of rituximab on lipids, arterial stiffness and carotid intima-media thickness in rheumatoid arthritis. J. Korean Med. Sci. 2016, 31, 202–207.
  60. Mathieu, S.; Pereira, B.; Dubost, J.J.; Lusson, J.R.; Soubrier, M. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology 2012, 51, 1107–1111.
  61. Benucci, M.; Saviola, G.; Manfredi, M.; Sarzi-Puttini, P.; Atzeni, F. Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. Biologics 2013, 7, 69–75.
  62. Hsue, P.Y.; Scherzer, R.; Grunfeld, C.; Imboden, J.; Wu, Y.; Del Puerto, G.; Nitta, E.; Shigenaga, J.; Schnell Heringer, A.; Ganz, P.; et al. Depletion of B-cell rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. J. Am. Heart Assoc. 2014, 3, e001267.
  63. Van Vollenhove, R.F.; Emery, P.; Bingham, C.O.; Keystone, E.C.; Fleischmann, R.M.; Furst, D.E.; Tyson, N.; Collinson, N.; Lehane, P.B. Long-term safety of rituximab in rheumatoid arthritis: 9.5 years follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. 2013, 72, 1496–1502.
  64. Ewing, M.M.; Karper, J.C.; Abdul, S.; de Jong, R.C.M.; Peters, H.A.B.; de Vries, M.R.; Redeker, A.; Kuiper, J.; Toes, R.E.M.; Arens, R.; et al. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int. J. Cardiol. 2013, 168, 1965–1974.
  65. Pappas, D.A.; John, A.; Curtis, J.A.; Reed, G.W.; Greenberg, J.D.; Shewade, A.; Solomon, D.H.; Kremer, J.M.; Soomers, T. Effect of biological agents on lipid and cardiovascular risk in rheumatoid arthritis. Ann. Rheum. Dis. 2013, 72, 49.
  66. Saito, K.; Hanami, K.; Hirata, S.; Kubo, S.; Nawata, M.; Yamaoka, K.; Nakayamada, S.; Nakano, K.; Tanaka, Y. Comparison of lipid profile including high molecular weight adiponectin (HMW-AN) after treatment with three different biologics in the patients with bio-naïve rheumatoid arthritis. Ann. Rheum. Dis. 2014, 72, 459.
  67. Charles-Schoeman, C.; Gugiu, G.B.; Ge, H.; Shahbazian, A.; Lee, Y.Y.; Wang, X.; Furst, D.E.; Ranganath, V.K.; Maldonado, M.; Lee, T.; et al. Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis. Artheriosclerosis 2018, 275, 107–114.
  68. Mathieu, S.; Couderc, M.; Glace, B.; Pereira, B.; Tournadre, A.; Dubost, J.J.; Soubrier, M. Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis. Biologics 2013, 7, 259–264.
  69. Ursini, F.; Russo, E.; Hribal, M.L.; Mauro, D.; Savarino, F.; Bruno, C.; Tripolino, C.; Rubino, M.; Naty, S.; Grembiale, R.D. Abatacept improves whole body insulin sensitivity in rheumatoid arthritis: An observational study. Medicine 2015, 94, e888.
  70. Jin, Y.; Kang, E.H.; Brill, G.; Desai, R.J.; Kim, S.C. Cardiovascular risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline cv disease. J. Rheumatol. 2018, 45, 1240–1248.
  71. Kang, E.H.; Jin, Y.; Brill, G.; Lewey, J.; Patorno, E.; Desai, R.J.; Kim, S.C. Comparative cardiovascular risk of abatacept tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: A multidatabase cohort study. J. Am. Heart Assoc. 2018, 24, e001393.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback